Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi reports positive phase III trial data for Lyxumia

Sanofi reports positive phase III trial data for Lyxumia

2nd June 2011

Sanofi has announced positive clinical trial data for its new drug Lyxumia, showing its efficacy as an add-on treatment for type 2 diabetes.

The investigational compound was evaluated in a phase III study called GetGoal-L, in which it was utilised as an add-on to basal insulin treatment and compared to placebo among a group of 495 patients.

It was found that those using the Lyxumia-based therapy experienced a significant reduction in glycated haemoglobin levels without a significant increase in their risk of hypoglycaemia.

This was one of nine studies in the GetGoal clinical programme for the lixisenatide-based treatment, which is yet to receive regulatory approval anywhere in the world.

Pierre Chancel, senior vice-president for the global diabetes division at Sanofi, said: "The findings from this and previous studies reinforce a continuing positive trend demonstrating the potential of lixisenatide to improve the lives of people with type 2 diabetes."

In April 2011, the company reported results from GetGoal-S, in which the drug showed efficacy among patients whose condition was inadequately controlled by sulfonylurea.ADNFCR-8000103-ID-800564766-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.